Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Large ribosomal subunit protein uL1 is a highly conserved structural component of the large 60S/50S subunit of both prokaryotic and eukaryotic ribosomes. It binds directly to 23S rRNA within the so-called "L1 stalk," which is mobile within the assembled particle. This mobility allows it to participate actively in releasing deacylated tRNAs from the E site during translation termination or translocation steps. The human version is encoded by RPL10A; alternative names include NEDD6 and CSA19 among others. While not typically considered a classical drug target outside antibacterial therapy, it can be targeted by antibiotics such as clindamycin that exploit differences between bacterial and mammalian translational machinery for selective inhibition.[1][5][9]
Drugs like clindamycin inhibit bacterial translation by targeting the large ribosomal subunit—specifically interfering with peptide elongation or tRNA translocation at the E site where uL1 plays a role[1].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Large ribosomal subunit protein uL1 (uL1).